Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Odontogenic Cysts 2Lung Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Nose Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

lutetium Lu 177 dotatate 20Magnetic Resonance Spectroscopy 10pembrolizumab 9Specimen Handling 7Everolimus 7cabozantinib 6Nivolumab 6lenvatinib 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5surufatinib 4amino-acid, glucose, and electrolyte solution 4Capecitabine 4olaparib 3lanreotide 3atezolizumab 3Temozolomide 3Octreotide 3Lutetium-177 3Ipilimumab 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2X-Rays 2Radiotherapy 2Phantoms, Imaging 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Radionuclide Imaging × 1 year × Clear all
NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Active not recruiting
11 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡